Analytics in Life Sciences

CRA specializes in assessing and improving existing forecasts as well as building new ones. The deep statistical expertise of our advanced analytics team allows us to offer sophisticated and customized analyses with a quick turnaround, including advanced time series modeling and probabilistic Monte Carlo simulation to assess risk and sensitivity of outputs. Our broad experience in product portfolios means familiarity with and access to a wide variety of relevant analog information across therapeutic areas, which pairs well with our technical capability to convert available primary and secondary data into actionable recommendations on forecast assumptions.

As the healthcare industry has evolved, market interactions have become increasingly complex, with high degrees of inter-dependencies across diverse stakeholders. We leverage our analytics expertise to mine and integrate insights across stakeholders and geographies. CRA’s team is deeply experienced with a wide range of data sources, including patient-level claims, EHR/EMR, managed markets data and account-level sales data, among others. We help life science organizations (pharmaceutical, biotechnology, medical device, and diagnostic markets) understand, current market dynamics, and how the market will evolve and how to develop and commercialize your asset to maximize success.

Each health care provider is part of formal and informal networks in which they share patients, information, and clinical decisions. A better understanding of physician network dynamics could enable clients to decrease marketing costs and more effectively identify top influencing physicians. CRA’s approach considers three aspects: the relationships among physicians, the relationships between physicians and patients, and the relationships between physicians and other health providers, by leveraging multiple data sources including claims data, clinical trial data and other public data. Combined with machine-learning models and interactive visualizations, our deliverable allows clients to easily navigate to national or regional HCP networks and access comprehensive profiles of each provider for a specific therapeutic area.

Leveraging rich patient-level longitudinal data covering ~300 million US patients and billions of transactions, CRA helps clients characterize patients with complex care pathways and understand the therapeutic landscape and prescribing trends within a disease, creating a detailed roadmap of the treatment journey. CRA’s solution delivers a comprehensive market opportunity assessment, patients’ characterization, and a diagnosis and treatment journey analysis.

Pricing strategy is one of those most visible and politically sensitive decisions that life sciences companies need to make, and it has a clear impact on bottom-line performance. CRA’s rigorous, holistic, and analytics-driven approach can help bring confidence and clarity to decision-making on pricing. Our analyses can provide the foundation for indication and geographic launch sequencing to maximize an asset’s or franchise’s value over the lifecycle at global and local levels. We also support the implementation of pricing and contracting guidance to affiliate teams, capturing nuanced differences between countries archetypes, reimbursement channels, and payer segments (e.g., US PBMs and health plans).